Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has t...

Full description

Bibliographic Details
Main Authors:	Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Cells
Subjects:	epidermal growth factor receptor non-small cell lung cancer drug resistance tyrosine kinase inhibitor monoclonal antibody
Online Access:	https://www.mdpi.com/2073-4409/10/5/1206

Similar Items

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
by: Sviatoslav Chekhun, et al.
Published: (2023-12-01)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
by: Ying-Yi Chen, et al.
Published: (2023-10-01)

Immunohistochemical analysis of epidermal growth factor receptor as a predictive biomarker in lung adenocarcinoma – A cross-sectional study of 33 cases on computed tomography-guided core needle biopsy specimens
by: Sajeeb Mondal, et al.
Published: (2024-01-01)

Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer
by: Terry W. Moody, et al.
Published: (2023-07-01)

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
by: Sathishbabu Paranthaman, et al.
Published: (2020-12-01)

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung
by: Chia‐Yu Kuo, et al.
Published: (2024-05-01)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O’Leary, et al.
Published: (2020-09-01)

The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases
by: Jianxi Zhou, et al.
Published: (2024-01-01)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Katsuhiro Masago, et al.
Published: (2018-01-01)

Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study
by: Hui-Hsia Hsieh, et al.
Published: (2023-02-01)

Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
by: Philomena Charlotte Dsouza, et al.
Published: (2017-01-01)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
by: Ping-Chih Hsu, et al.
Published: (2023-10-01)

Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer
by: Bingwan XIONG, et al.
Published: (2024-04-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor
by: Antonia A. Högnäsbacka, et al.
Published: (2024-02-01)

Mutation Analysis of Epidermal Growth Factor Receptor Gene in Non-Small Cell Lung Cancer for Selection of Patients Eligible for Tyrosine Kinase Inhibitor Therapy
by: Zeeshan Ansar, et al.
Published: (2023-12-01)

Evaluation of the prognostic value of the new 9th edition Tumor-Node-Metastases (TNM) staging system for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with bone metastases
by: Jin Peng, et al.
Published: (2024-10-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Progress on the impact of lipid metabolism reprogramming on resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer
by: XIAO Xinyao, GUO Shunyao, LU Haiyan, SHEN Hua
Published: (2024-01-01)

What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2024-12-01)

The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review
by: Yutaka Fujiwara, et al.
Published: (2024-06-01)

Onset of takotsubo syndrome induced by osimertinib in a patient with lung adenocarcinoma
by: Shouichi Okamoto, et al.
Published: (2024-01-01)

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
by: Ling Zhang, et al.
Published: (2023-05-01)

Probing Structure and Function of Alkali Sensor IRR with Monoclonal Antibodies
by: Alexander S. Goryashchenko, et al.
Published: (2020-07-01)

Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review
by: Mousa Alali, et al.
Published: (2023-08-01)

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients
by: Xin Nie, et al.
Published: (2025-03-01)

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach
by: Francesca Di Pressa, et al.
Published: (2024-05-01)

Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review
by: Kenya Miyamoto, et al.
Published: (2024-01-01)

Unusual response with tyrosine kinase inhibitor in small-cell lung cancer
by: Aashita, et al.
Published: (2024-08-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-11-01)

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients
by: Ji Su Lee, et al.
Published: (2024-08-01)

Ginsenoside CK ameliorates tumor growth in lung cancer mice via inhibiting EGFR
by: Yuan Liang, et al.
Published: (2024-10-01)

Benzotriazole UV stabilizers disrupt epidermal growth factor receptor signaling in human cells
by: Natalie C. Sondermann, et al.
Published: (2024-08-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Bilateral keratitis associated with afatinib therapy
by: Ya-Tung Liu, et al.
Published: (2024-01-01)

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment
by: Qizhi Ma, et al.
Published: (2023-10-01)

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis
by: Xueming Xia, et al.
Published: (2024-07-01)

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
by: Toshiki Morimoto, et al.
Published: (2023-10-01)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
by: Paola Ulivi, et al.
Published: (2021-09-01)